Resistance, aerobic exercise improves quality of life in older long-term survivors of prostate cancer
the ONA take:
A recent study demonstrated that aerobic and resistance exercise appears to have beneficial effects on health-related quality of life (HRQoL).
The researchers examined effects, moderators, and mediators of 12 months of exercise on HRQoL in older long-term survivors.
The study included a total of 100 men who were randomized to two groups. The exercise (EX) group had 6 months of supervised aerobic and resistance exercise followed by 6 months of a home-based maintenance program.
The physical activity (PA) group were given printed material regarding physical activity for 12 months. The participants were assessed at 6 and 12 months.
The EX group demonstrated significant benefits in global QoL, physical function, and social function compared with the PA group at 6 months.
In addition, the effects on physical function were sustained at 12 months. Moderating factors included marital status, initiation of exercise sooner after diagnosis, and previous use of bisphosphonates.
Aerobic and resistance exercise appears to have beneficial effects on health-related quality of life.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Clinical Trials May Benefit Oncology Patients
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Prostate-specific PET and CT Imaging Improves Detection of Disease and Patient Care
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Breast Cancer Diagnosis and Nurse Navigation Survey
- Rates at Some Milestones May Indicate Clinical Trial Results for Immunotherapeutics
- Cancer Risks for BRCA1/2 Mutation Carriers Determined by Age, Family History, Mutation Location
- Long-Term Use of TPO Receptor Agonist Safe in CLL-Associated Immune Thrombocytopenia
- Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer
- Radiotherapy is Essential in Treating Brain Tumors But Associated With Significant Adverse Events
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|